Avalon GloboCare (ALBT) Competitors $2.71 -0.07 (-2.52%) (As of 12:15 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends ALBT vs. CYCN, ATIF, EVGN, RVYL, NKGN, AWH, TSBX, CDT, INDP, and PHXMShould you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include Cyclerion Therapeutics (CYCN), ATIF (ATIF), Evogene (EVGN), Ryvyl (RVYL), NKGen Biotech (NKGN), Aspira Women's Health (AWH), Turnstone Biologics (TSBX), Conduit Pharmaceuticals (CDT), Indaptus Therapeutics (INDP), and PHAXIAM Therapeutics (PHXM). Avalon GloboCare vs. Cyclerion Therapeutics ATIF Evogene Ryvyl NKGen Biotech Aspira Women's Health Turnstone Biologics Conduit Pharmaceuticals Indaptus Therapeutics PHAXIAM Therapeutics Cyclerion Therapeutics (NASDAQ:CYCN) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their community ranking, dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation. Which has more volatility & risk, CYCN or ALBT? Cyclerion Therapeutics has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Is CYCN or ALBT more profitable? Cyclerion Therapeutics has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,125.59%. Avalon GloboCare's return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cyclerion TherapeuticsN/A -55.32% -48.35% Avalon GloboCare -1,125.59%N/A -73.69% Does the MarketBeat Community prefer CYCN or ALBT? Cyclerion Therapeutics received 34 more outperform votes than Avalon GloboCare when rated by MarketBeat users. CompanyUnderperformOutperformCyclerion TherapeuticsOutperform Votes3458.62% Underperform Votes2441.38% Avalon GloboCareN/AN/A Which has higher earnings and valuation, CYCN or ALBT? Cyclerion Therapeutics has higher revenue and earnings than Avalon GloboCare. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclerion Therapeutics$1.62M2.96-$5.26MN/AN/AAvalon GloboCare$1.26M2.34-$16.71M-$19.96-0.14 Do institutionals & insiders believe in CYCN or ALBT? 75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 36.1% of Cyclerion Therapeutics shares are held by company insiders. Comparatively, 37.3% of Avalon GloboCare shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor CYCN or ALBT? In the previous week, Avalon GloboCare had 3 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 4 mentions for Avalon GloboCare and 1 mentions for Cyclerion Therapeutics. Avalon GloboCare's average media sentiment score of 0.28 beat Cyclerion Therapeutics' score of 0.00 indicating that Avalon GloboCare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cyclerion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avalon GloboCare 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCyclerion Therapeutics beats Avalon GloboCare on 8 of the 12 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Avalon GloboCare News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALBT vs. The Competition Export to ExcelMetricAvalon GloboCareBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.95M$2.97B$5.09B$8.79BDividend YieldN/A1.91%5.04%4.07%P/E Ratio-0.1418.1093.0914.02Price / Sales2.34281.591,220.6787.41Price / CashN/A169.3839.4936.27Price / Book-0.204.406.936.33Net Income-$16.71M-$41.63M$118.83M$225.71M7 Day Performance-10.26%-5.26%-1.74%-0.58%1 Month Performance-9.67%-7.03%-3.60%1.49%1 Year Performance-65.91%25.64%31.91%27.23% Avalon GloboCare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALBTAvalon GloboCare0.8367 of 5 stars$2.71-2.5%N/A-66.0%$2.95M$1.26M-0.145CYCNCyclerion Therapeutics0.9821 of 5 stars$1.77-15.3%N/A-7.7%$4.80M$1.62M0.0030Gap DownHigh Trading VolumeATIFATIF0.763 of 5 stars$0.65+4.8%N/A-37.2%$7.78M$620,000.000.0010Gap UpEVGNEvogene2.2613 of 5 stars$1.49-9.7%$12.00+705.4%-73.9%$8.00M$5.64M-0.42140Analyst ForecastNews CoverageGap DownRVYLRyvyl0.9702 of 5 stars$1.19-1.7%N/A-51.6%$8.81M$65.87M0.0050Gap UpNKGNNKGen BiotechN/A$0.33+5.0%N/A-89.1%$11.62M$80,000.00-0.06N/AGap UpAWHAspira Women's Health1.533 of 5 stars$0.70-3.6%$4.40+525.0%-78.5%$11.31M$9.15M-0.64110Analyst ForecastTSBXTurnstone Biologics3.2023 of 5 stars$0.48+4.8%$2.13+340.9%-84.8%$11.15M$19.31M0.0082CDTConduit PharmaceuticalsN/A$0.11+21.5%N/A-92.8%$10.76MN/A0.003News CoverageGap UpHigh Trading VolumeINDPIndaptus Therapeutics2.7304 of 5 stars$1.04-1.9%$8.50+717.3%-48.7%$10.61MN/A0.006PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049 Related Companies and Tools Related Companies Cyclerion Therapeutics Competitors ATIF Competitors Evogene Competitors Ryvyl Competitors NKGen Biotech Competitors Aspira Women's Health Competitors Turnstone Biologics Competitors Conduit Pharmaceuticals Competitors Indaptus Therapeutics Competitors PHAXIAM Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALBT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
